Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial

Niraparib as maintenance for platinum-sensitive ovarian cancer - results from ENGOT-OV16/NOVA trialПодробнее

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancerПодробнее

Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancerПодробнее

Comment: Niraparib for ovarian cancerПодробнее

Dr. Mirza on the Phase III NOVA Trial in Ovarian CancerПодробнее

Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancerПодробнее

Results of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancerПодробнее

Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprisingПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

Design of the NOVA Trial for Ovarian CancerПодробнее

NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patientsПодробнее

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Niraparib significantly improves outcomes for ovarian cancer patientsПодробнее

Niraparib Maintenance for Recurrent Ovarian CancerПодробнее

The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Niraparib Maintenance Therapy for Ovarian CancerПодробнее

Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Case 1: Use of Niraparib in Ovarian CancerПодробнее